Lumos Pharma — Technical Presentation (November 2023)
37 slides from Lumos Pharma's technical presentation, Nov 7, 2023
Slide 1: Phase 2 Topline Results LUM-201 for Pediatric Growth Hormone Deficiency
1 Phase 2 Topline Results LUM-201 for Pediatric Growth Hormone Deficiency OraGrowtH210 and OraGrowtH212 November 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Phase 2 Data Provides Clear Path to Phase 3 in PGHD
3 Phase 2 Data Provides Clear Path to Phase 3 in PGHD 1 AHV = Least Squares Mean Annualized Height Velocity, throughout this presentation AHV values from the OraGrowth studies are based on ANCOVA model (details provided on subsequent slides) LUM-201 1.6 mg/kg/day dose AHV at 6 months and 12 months
Slide 4: LUM-201 Stimulates Natural Growth Hormone Secretion
4 LUM-201 Stimulates Natural Growth Hormone Secretion • LUM-201 is an oral GH secretagogue* • Acts on specific receptors in hypothalamus and pituitary to stimulate release of GH1 • Increases the amplitude of natural pulsatile GH secretion2,3 • LUM-201 stimulated GH release regulated by natural GH/IG
Slide 5: PEMs Enrich Trials for Patients Likely to Respond to LUM-201
5 PEMs Enrich Trials for Patients Likely to Respond to LUM-201 Responders to LUM-2012 Non-Responders to LUM-201 Moderate PGHD PEM-Positive ~60% of total PGHD population1 Severe PGHD PEM-Negative ~40% of total PGHD population Predictive Enrichment Marker Positive (PEM+) • Baseline IGF-1 > 30 ng/ml •
Slide 6: OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD
6 OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD n = ~20 Daily rhGH injection n = ~20 LUM-201: 3.2 mg/kg/day n = ~20 LUM-201: 1.6 mg/kg/day n = ~20 LUM-201: 0.8 mg/kg/day • n = 82 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~4
Slide 7: OraGrowtH210 Baseline Demographics
7 OraGrowtH210 Baseline Demographics LUM-201 0.8 mg Mean (SD) N=18 LUM-201 1.6 mg Mean (SD) N=22 LUM-201 3.2 mg Mean (SD) N=22 rhGH Mean (SD) N=19 Age (months) 101.3 (29.2) 95.2 (27.3) 94.5 (21.1) 90.7 (23.7) Height (cm) 116.4 (12.4) 113.6 (11.0) 113.8 (9.2) 112.9 (10.7) Height SDS -2.32 (0.30) -2.3
Slide 8: OraGrowtH210 Met Primary Statistical Objective: PEM enriches responder population
8 • PEM test ensures patients enrolled in the study are capable of secreting GH in response to a single-dose of LUM-201 • PEM-positive criteria: o PGHD patients with baseline IGF-1 >30 ng/ml o Peak stimulated GH ≥ 5 ng/ml after a single 0.8 mg/kg dose of LUM-201 no enrich 0.8 PEM 1.6 PEM 3.2 PEM 0 5
Slide 9: PEM Test Reproducibility
9 PEM Test Reproducibility Subjects with Positive Agreement on PEM Tests 76/76 Reproducibility Rate 100% 95% Confidence Interval (95.3%, 100%) OraGrowtH210 Secondary Statistical Objective: PEM test yields highly reproducible results PEM positive classification was 100% reproducible and exceeded pre-
Slide 10: OraGrowtH210 Met Primary Objective: 6-Month AHV Supports 1.6 mg/kg
10 OraGrowtH210 Met Primary Objective: 6-Month AHV Supports 1.6 mg/kg as Optimal Dose for Phase 3 AHV ANCOVA Model Terms: treatment, Age at dose 1, Sex, Baseline HT SDS, Baseline BMI SDS, Baseline IGF-1 SDS, LUM-201 PEM, Baseline BA Delay, HT SDS-MPH SDS Bars represent Least Squares Mean (LSM), Erro
Slide 11: OraGrowtH210: 12-Month AHV Data Growth Rates are Durable
11 • 1.6 mg/kg best performing LUM-201 cohort o Growth of 8.0 cm comparable to historical 12-month AHV for moderate population • 1.7 cm difference between 1.6mg/kg and rhGH cohorts o Differences less than 1.8 – 2.0 cm have been the historical Phase 3 non-inferiority margin for rhGH approvals AHV ANC
Slide 12: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets
12 LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets *Daily Genotropin control group for Somatrogon Ph3 dosed at 0.034 mg/kg/day (equates to 0.24 mg/kg/wk); subjects were stratified based on GH production during a standard stim test. 1.6 m g/k g 6m 1.6 m g/k g 12 m GeN eS IS iPGHD K
Slide 13: OraGrowtH210 Phase 2: IGF-1 Standard Deviation Score
13 OraGrowtH210 Phase 2: IGF-1 Standard Deviation Score (SDS) LUM-201 Normalizes IGF-1 SDS with Durable Effect out to 12 months baseline 0.8 1.6 3.2 rhGH -2 -1 0 1 2 9 0.74 0.14 -0.21 11 -0.48 41 -1.38 210 IGF-1 SDS 12m data PP12 IG F- 1 SD S mg/kg LUM-201 n=11 n=12 • LUM-201 normalizes IGF-1 within
Slide 14: OraGrowtH210 Summary
14 All primary and secondary endpoints met LUM-201 AHV’s consistent with pre-specified targets from historical benchmarks in moderate PGHD population AHV delta for LUM-201 1.6 mg/kg from comparator daily rhGH arm at 6- and 12-months is within the non-inferiority margin (difference less than 1.8 t
Slide 15: OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD
15 • n = 22 • Open-label study • Moderate PGHD patients • rhGH-treatment naïve • Dosing to near-adult height • Single, specialized clinical site in Santiago, Chile • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD Study Endpoints: • Assess LUM-201 effect on
Slide 16: OraGrowtH212 Trial Baseline Demographics
16 OraGrowtH212 Trial Baseline Demographics LUM-201 1.6 mg Mean (SD) N=11 LUM-201 3.2 mg Mean (SD) N=11 Age (months) 99.7 (15.2) 100.9 (21.1) Height (cm) 116.5 (5.5) 116.6 (9.5) Height SDS -2.15 (0.28) -2.26 (0.38) IGF-1 SDS -1.01 (0.64) -0.85 (0.50) MPH (cm) 162.6 (7.0) 160.3 (8.7) MPH SDS ∆ -0.85
Slide 17: OraGrowtH212: Significant Increase in Growth from Baseline AHV at 6 Months
17 • AHV at 6 months: o 7.4 in the 1.6 mg/kg arm o 7.7 in the 3.2 mg/kg arm • OraGrowtH212 is a single-site study with a seemingly more homogeneous population than those enrolled in the global OraGrowtH210 OraGrowtH212: Significant Increase in Growth from Baseline AHV at 6 Months • AHV = Annualized
Slide 18: OraGrowtH212: Significant Growth from Baseline Per Protocol 12-Month Population
18 • Significant increase in growth from baseline • Durable effect to 12 months • Minimal drop off in AHV between 6 and 12 months • No material difference between 2 dose cohorts at 6 or 12 months OraGrowtH212: Significant Growth from Baseline Per Protocol 12-Month Population: 6 and 12-Month AHVs 1.6
Slide 19: OraGrowtH212 Phase 2: IGF-1 SDS
19 base 1.6 6m 3.2 6m -1.5 -1.0 -0.5 0.0 0.5 1.0 11 0.47 0.14 22 -0.93 IGF-1 SDS - 6m cohort IG F- 1 SD S n=11 base 1.6 12m 3.2 12m -1.5 -1.0 -0.5 0.0 0.5 1.0 7 0.30 -0.03 15 -0.87 IGF-1 SDS - 12m cohort IG F- 1 SD S n=8 • Bars represent sample mean • Error bars represent SEM • Data represent number
Slide 20: OraGrowtH212: LUM-201 Normalizes GH Concentrations in Moderate PGHD
20 LUM-201 stimulates an increase in pulsatile secretion of GH approximating normal physiologic levels ‡ IC-GH: integrated concentration of Growth Hormone; data represent mean + standard deviation *GH concentrations from the combined 1.6 and 3.2 mg/kg/day cohorts † Zadik et al Horm Res 1992 Notes fo
Slide 21: OraGrowtH212: LUM-201 Normalizes GH Concentrations in Moderate PGHD
21 Time period Normal healthy (IC-GH‡) Untreated GHD (IC-GH‡) LUM-201 (baseline GH)* LUM-201 (treat 6M GH)* Comparator arm rhGH 34 µg/kg/day Zadik† N = 22 Albertsson- Wikland†† 12h (day) µg/kg.12hr 3.3 + 1.3 1.1 + 0.5 1.3 2.6 - 24h µg/kg/24hr 5.0 + 1.3 1.4 + 0.5 1.7 3.3 – 4.0 ~20 µg/kg/24hr†† Ratio
Slide 22: OraGrowtH212 Summary
22 OraGrowtH212 Summary All primary and secondary endpoints met Increased 6- and 12-month AHV meaningfully from baseline LUM-201 normalized IGF-1 SDS values within 6 months of treatment with durable effect LUM-201 stimulates an increase in pulsatile secretion of GH approximating normal physio
Slide 23: LUM-201 Data Suggests Greater Durability of Response than rhGH to 24 Months
23 AHV values from the OraGrowth studies are based on ANCOVA model (details provided on previous slides) * At 24 months, data include a subset of subjects from OraGrowtH210 trial who met protocol criteria to continue past 12 months. ** Ranke et.al. 2010 – rhGH treated cohort of moderate GHD children
Slide 24: Safety Data from Combined Trials
24 PEM 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg rhGH N =129 N =18 N =33 N=33 N =20 Number of AEs 38 59 155 150 54 Subjects with AE (%) 24 (18.6%) 14 (77.8%) 31 (93.9%) 30 (90.9%) 16 (80.0%) Treatment Related AEs * 7 2 17 20 6 Subjects with Treatment Related AEs (%) 4 (3.1%) 1 (5.6%) 13 (39.4%) 13 (39.4%) 5 (25
Slide 25: Lumos Pharma Financial Information as of September 30, 2023
25 Lumos Pharma Financial Information as of September 30, 2023 Values in USD Cash, equivalents & short-term investments $42.7M Debt $0 Shares Outstanding 7.9M Cash Use for 4Q 2023 ~ $9.0-$10.0M Fiscal Year End December 31 LUMO Cash, cash equivalents, & short-term investments to support operations th
Slide 26: Recap Summary and Next Steps
26 Recap Summary and Next Steps o Met all primary and secondary endpoints o LUM-201 increases pulsatility, restores GH secretion and normalizes IGF-1 o LUM-201 promotes growth comparable to rhGH with only 20% of GH concentration levels o Optimal 6-month LUM-201 dose vs rhGH AHV delta (1.8 cm) within
Slide 27: Supplementary Materials
Supplementary Materials
Slide 28: Safety Profile at Interim Analysis for OraGrowtH210 Trial
28 Safety Profile at Interim Analysis for OraGrowtH210 Trial 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg ALL LUM-201 rhGH 34 mcg/kg N = 18 22 22 62 20 Number of AEs 59 79 74 212 54 Subjects with AE (%) 14 (77.8%) 20 (90.9%) 19 (86.4%) 53 (85.5%) 16 (80.0%) Treatment Related AEs (N) 2 2 4 8 6 Subjects with Treatme
Slide 29: Related AEs – Preferred Term
29 Related 210 AEs – Preferred Term, N (%) 0.8 N=18 1.6 N=22 3.2 N=22 ALL N= 62 rhGH N=20 Comments Contusion -- -- -- -- 1 (5.0) Grade 1, Recovered by next visit Injection Site Bruising -- -- -- -- 2 (10.0) Grade 1, Recovered by next visit Increased Appetite (All Grade 1) 1 (5.6) 1 (4.5) 1 (4.5) 3 (
Slide 30: Serious Adverse Events
30 Serious Adverse Events 210 Trial Serious Adverse Event System Organ Class Gr Study Treatment Relatedness Serious Criteria Product Administration Error Injury, Poisoning and Procedural Complications 1 NA (occurred prior to receiving any study drug) Unrelated Hosp Dehydration Metabolism and Nutriti
Slide 31: Related AEs – Preferred Term (OraGrowtH212)
31 Related 212 AEs – Preferred Term, N (%) 1.6 N=11 3.2 N=11 ALL N=22 Comments Abdominal Pain 1 (9.1) -- 1 (4.5) Grade 1, Duration: few days Transaminases Increased -- 1 (9.1) 1 (4.5) Grade 1, Duration: <3 months Increased Appetite 11 (100.0) 10 (90.9) 21 (95.5) 19 Grade 1 9 ongoing 10 resolved (dur
Slide 32: Specific OraGrowtH210 AEs – No meaningful signal
32 Specific OraGrowtH210 AEs – No meaningful signal safety data available for 82 subjects at interim analysis 0.8 N=18 1.6 N=22 3.2 N=22 ALL N=62 rhGH N=20 Arthralgia 2 (11.1%) 3 (13.6%) 2 (9.1%) 7 (11.3%) 2 (10.0%) Myalgia 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (15.0%) Headache 5 (27.8%) 7 (31.8%) 5
Slide 33: Laboratory Shifts: No meaningful signal
33 Laboratory Shifts: No meaningful signal 82 subjects 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 ALT Nl to high 2/17 (11.8%) 5/22 (22.7%) 4/22 (18.2%) 11/61 (18%) 7/20 (35%) AST Nl to high 3/14 (21.4%) 4/21 (19%) 5/22 (22.7%) 12/57 (21.1%) 6/20 (30%) Bicarb Nl to high 0/18 (0%)
Slide 34: Laboratory Shifts
34 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Urea nitro Nl to low 4/18 (22.2%) 4/21 (19%) 7/22 (31.8%) 15/61 (24.6%) 7/20 (35%) Urea nitro Nl to high 1/18 (5.6%) 0/22 (0%) 1/22 (4.5%) 2/62 (3.2%) 0/20 (0%) Basophils Nl to high 7/17 (41.2%) 12/22 (54.5%) 10/21
Slide 35: Laboratory Shifts
35 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Globulin Nl to low 6/18 (33.3%) 4/22 (18.2%) 4/22 (18.2%) 14/62 (22.6%) 5/20 (25%) Glucose Nl to high 0/18 (0%) 5/22 (22.7%) 6/22 (27.3%) 11/61 (18%) 0/20 (0%) Glucose Nl to low 0/18 (0%) 0/22 (0.0%) 1/22 (4.5%) 1/6
Slide 36: Laboratory Shifts
36 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Ery. crp. Hb Nl to low 2/17 (11.8%) 2/22 (9.1%) 3/22 (13.6%) 7/61 (11.5%) 2/20 (10%) Ery. crp. vol Nl to low 1/18 (5.6%) 3/21 (14.3%) 3/22 (13.6%) 7/61 (11.5%) 1/20 (5%) Ery. crp vol Nl to high 0/17 (0.0%) 0/22 (0.0
Slide 37: Laboratory Shifts: No meaningful signal
37 Laboratory Shifts: No meaningful signal 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Eryth. Nl to high 1/17 (5.9%) 2/22 (9.1%) 2/22 (9.1%) 5/61 (8.2%) 1/20 (5%) Eryth. Nl to low 1/18 (5.6%) 0/22 (0.0%) 0/22 (0.0%) 1/62 (1.6%) 0/20 (0%) Leukocyt. Nl to high 1/17 (5.9%) 2/22 (9.1
Lumos Pharma — Technical Presentation (November 2023) on 6ix